Fluoroquinolones for Respiratory Infection [PDF]
Chest, 2002 Karl Heinz Weiss, Glenn S. Tillotson
+4 more sources
Respiratory Fluoroquinolones: Differences in the Details [PDF]
Clinical Infectious Diseases, 2004 Lionel A. Mandell +2 more
openalex +2 more sources
Role of newer fluoroquinolones in lower respiratory tract infections [PDF]
Journal of Antimicrobial Chemotherapy, 2002 The impact of respiratory infections on inviduals in society is important and is growing as the population ages. Lower respiratory tract infections in particular are major causes of morbidity and mortality. These infections include acute exacerbation of chronic bronchitis (AECB) and community- acquired pneumonia.
H. Lode
openalex +5 more sources
Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract [PDF]
European Respiratory Journal, 1999 Pharmacokinetic and pharmacodynamic features are important predictors of the therapeutic efficacy of an antibiotic. In respiratory tract infection, study of the clinical implication of pharmacodynamic features is complicated as infection occurs at several distinct sites.
Robert A. Wise, D. Honeybourne
openalex +4 more sources
The role of fluoroquinolones in respiratory tract infections [PDF]
Journal of Antimicrobial Chemotherapy, 1997 Quinolones, because of their excellent pharmacokinetic properties, high antimicrobial activity and low incidence of side-effects, have been broadly accepted for the treatment of many infections. Because of perceived limitations against Streptococcus pneumoniae and methicillin-resistant Staphylococcus aureus there has been some reluctance to use them ...
Ronald F. Grossman
openalex +3 more sources
Upper respiratory tract infections: etiology, current treatment, and experience with fluoroquinolones [PDF]
Clinical Microbiology and Infection, 1998 Javier Garau +4 more
openalex +3 more sources
Lower respiratory tract infections: etiology, current treatment, and experience with fluoroquinolones [PDF]
Clinical Microbiology and Infection, 1998 SCOPUS: cp.j ; info:eu-repo/semantics ...
Ethan Rubinstein +5 more
openalex +3 more sources
Newer Fluoroquinolones and the Management of Respiratory Tract Infections [PDF]
Clinical Infectious Diseases, 2000 Infections of the respiratory tract remain one of the leading causes of death in the United States [1]. The cost burden for bacterial infections of the upper and lower respiratory tract is tremendous; the cost alone of treating patients with communityacquired pneumonia (CAP) has recently been estimated to be close to $10 billion (US) [2].
Adolf W. Karchmer
openalex +3 more sources
Respiratory Fluoroquinolone Use and Influenza [PDF]
Infection Control & Hospital Epidemiology, 2011 We show that respiratory fluoroquinolone use is extremely seasonal and that fluoroquinolone use is strongly associated with influenza. In our time series model, instantaneous influenza activity was a significant predictor of use (P< .0001). Also, we estimated that reducing influenza activity by 20% would reduce prescriptions by 8%.
Philip M, Polgreen +3 more
openaire +2 more sources
Activities of New Fluoroquinolones against Fluoroquinolone-Resistant Pathogens of the Lower Respiratory Tract [PDF]
Antimicrobial Agents and Chemotherapy, 1998 ABSTRACT The activities of six new fluoroquinolones (moxifloxacin, grepafloxacin, gatifloxacin, trovafloxacin, clinafloxacin, and levofloxacin) compared with those of sparfloxacin and ciprofloxacin with or without reserpine (20 μg/ml) were determined for 19 Streptococcus pneumoniae isolates, 5 ...
Laura J. V. Piddock +3 more
openalex +3 more sources